The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer.

CONCLUSIONS: MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti-PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most MMR-D patients, supporting the earlier use of immune checkpoint inhibitors.
PMID: 32156744 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 9, 2020 Category: Cancer & Oncology Authors: Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Ishii G, Kuwata T, Shitara K Tags: Clin Cancer Res Source Type: research